Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications

Frontiers in Endocrinology

Volumn 3, Issue DEC, 2012, Pages

  Körner, Meike ^a   Christ, Emanuel ^b   Wild, Damian ^c   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

111In DOTA DPTA exendin 4; Glucagon like peptide 1; Glucagon like peptide 1 receptor; Insulinoma

Indexed keywords

EID: 84874430135     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00158     Document Type: Review

References (42)

1. Baggio, L.L., and Drucker, D.J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157.
2. Brom, M., Oyen, W. J., Joosten, L., Gotthardt, M., and Boerman, O. C. (2010). (68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur. J. Nucl. Med. Mol. Imaging 37, 1345-1355.
3. Chatziioannou, A., Kehagias, D., Mourikis, D., Antoniou, A., Limouris, G., Kaponis, A., et al.(2001).Imaging and localization of pancreatic insulinomas. Clin. Imaging 25, 275-283.
4. Christ, E., Forrer, F., Wild, D., Clerici, T., Braendle, M., Maecke, H., et al. (2012). Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients. Neuroendocrinology 96, 24-24.
5. Christ, E., Wild, D., Forrer, F., Brandle, M., Sahli, R., Clerici, T., et al. (2009). Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 94, 4398-4405.
6. Christ, E., Wild, D., and Reubi, J. C. (2010). Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. Endocrinol. Metab. Clin. North Am. 39, 791-800.
7. Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., et al. (2007). 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48, 508-518.
8. Gotthardt, M., Fischer, M., Naeher, I., Holz, J. B., Jungclas, H., Fritsch, H. W., et al. (2002). Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur.J.Nucl.Med.Mol. Imaging 29, 597-606.
9. Gros, L., Thorens, B., Bataille, D., and Kervran, A. (1993). Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact withacommonreceptorina somatostatin-secreting cell line. Endocrinology 133, 631-638.
10. Hanahan, D. (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122.
11. Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., et al. (2011). Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metasta-sized neuro endocrine cancers. J. Clin. Oncol. 29, 2416-2423.
12. Kauhanen, S., Seppanen, M., Minn, H., Gullichsen, R., Salonen, A., Alanen, K., et al. (2007). Fluorine-18-L-dihy-droxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J. Clin. Endocrinol. Metab. 92, 1237-1244.
13. Kiesewetter, D. O., Gao, H., Ma, Y., Niu, G., Quan, Q., Guo, N., et al. (2012). 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 ininsulinoma.Eur.J.Nucl.Med.Mol. Imaging 39, 463-473.
14. Korner, M., Stockli, M., Waser, B., and Reubi, J. C. (2007). GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 48, 736-743.
15. Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., et al. (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA0, Tyr3]octreotate:toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124-2130.
16. Levine, J. A., Burgart, L. J., Batts, K. P., and Wang, K. K. (1995). Brunner's gland hamartomas: clinical presentation and pathological features of 27 cases. Am. J. Gastroenterol. 90, 290-294.
17. McAuley, G., Delaney, H., Colville, J., Lyburn, I., Worsley, D., Govender, P., et al. (2005). Multimodality preoperative imaging of pancreatic insulinomas. Clin. Radiol. 60, 1039-1050.
18. Montrose-Rafizadeh, C., Wang, Y., Janczewski, A. M., Henderson, T. E., and Egan, J. M. (1997). Over-expression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. Mol. Cell. Endocrinol. 130, 109-117.
19. Nauck, M.A. (2009).Unravelingthesci-enceofincretinbiology.Eur. J.Intern. Med. 20, S303-S308.
20. Nauck, M. A., Vilsboll, T., Gallwitz, B., Garber, A., and Madsbad, S. (2009). Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 32, S223-S231.
21. Plockinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., et al. (2004). Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 80, 394-424.
22. Reubi, J. C. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389-427.
23. Reubi, J. C., and Maecke, H. R. (2008).Peptide-basedprobesforcancer imaging. J. Nucl. Med. 49, 1735-1738.
24. Reubi, J. C., Perren, A., Rehmann, R., Waser, B., Christ, E., Callery, M., et al. (2010). Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperin-sulinaemic hypoglycaemia following gastricbypass.Diabetologia53, 2641-2645.
25. Reubi, J. C., and Waser, B. (2003). Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptortumortargeting.Eur. J. Nucl. Med. 30, 781-793.
26. Rostambeigi, N., and Thompson, G. B. (2009). What should be done in an operating room when an insulinoma cannot be found? Clin. Endocrinol. (Oxf.) 70, 512-515.
27. Service, G. J., Thompson, G. B., Service, F. J., Andrews, J. C., Collazo-Clavell, M. L., and Lloyd, R. V. (2005). Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N. Engl. J. Med. 353, 249-254.
28. Stolte, M., Schwabe, H., and Prestele, H. (1981). Relationship between diseases of the pancreas and hyperplasia of Brunner'sglands.Virchows Arch. A Pathol. Anat. Histol. 394, 75-87.
29. Tessonnier, L., Sebag, F., Ghander, C., De Micco, C., Reynaud, R., Palazzo, F. F., et al. (2010). Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J. Clin. Endocrinol. Metab. 95, 303-307.
30. Thompson, G.B., Service, F.J., Andrews, J. C., Lloyd, R. V., Natt, N., van Heerden, J. A., et al. (2000). Non-insulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 128, 937-944.
31. Thorens, B., Porret, A., Buhler, L., Deng, S. P., Morel, P., and Widmann, C. (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42, 1678-1682.
32. Waser, B., Beetschen, K., Pellegata, N. S., and Reubi, J. C. (2011). Incretin receptors in non-neoplastic and neo-plastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94, 291-301.
33. Wei, Y., and Mojsov, S. (1995). Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced aminoacidsequences.FEBSLett.358, 219-224.
34. Wicki, A., Wild, D., Storch, D., Seemayer, C., Gotthardt, M., Behe, M., et al. (2007). [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy forinsulinoma.Clin. Cancer Res. 13, 3696-3705.
35. Wiesli, P., Brandle, M., Schmid, C., Krahenbuhl, L., Furrer, J., Keller, U., et al. (2004). Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations.J.Vasc.Interv.Radiol. 15, 1251-1256.
36. Wild, D., Behe, M., Wicki, A., Storch, D., Waser, B., Gotthardt, M., et al. (2006). [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1(GLP-1)receptortargeting. J. Nucl. Med. 47, 2025-2033.
37. Wild, D., Caplin, M., Christ, E., Forrer, F., Brändle, M., Seufert, J., et al.(2011).Glucagon-likepeptide-1 vs. somatostatin receptor targeting in malignant insulinomas. J. Nucl. Med. 52, 1073-1078.
38. Wild, D., Christ, E., Forrer, F., Reubi, J. C., Maecke, H., Ell, P. J., et al. (2009). 111In-DTPA-exendin-4 SPECT/CT scans localize hardly detectable insulinomas. J. Nucl. Med. 50, 1937.
39. Wild, D., Mäcke, H., Christ, E., Gloor, B., and Reubi, J.C. (2008).Glucagon-like peptide1-receptor scans to localize occult insulinomas. N. Engl. J. Med. 359, 766-768.
40. Wild, D., Wicki, A., Mansi, R., Béhé, M., Keil, B., Bernhardt, P., et al. (2010). Exendin-4-based radio-pharmaceuticals for glucagons-like peptide-1 (GLP-1) receptor PET/CT and SPECT/CT imaging. J. Nucl. Med. 51, 1059-1067.
41. Wu, Z., Todorov, I., Li, L., Bading, J. R., Li, Z., Nair, I., et al. (2011). In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-exendin-4 by targeting GLP-1 receptor. Bioconjug. Chem. 22, 1587-1594.
42. Yakovac, W. C., Baker, L., and Hummeler, K. (1971). Beta cell nesidioblastosis in idiopathic hypoglycemia of infancy. J. Pediatr. 79, 226-231.